OncoMatch/Clinical Trials/NCT06405139
Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal Cancer
Is NCT06405139 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Nanoliposomal Irinotecan, Oxaliplatin plus Capecitabine for colorectal cancer.
Treatment: Nanoliposomal Irinotecan, Oxaliplatin plus Capecitabine — Neoadjuvant chemotherapy has gained acceptance in treating locally advanced breast cancer, esophageal cancer, gastric cancer, and rectal cancer. However, the role of neoadjuvant chemotherapy for locally advanced colon cancer is still in the exploratory stage. The objective of this study is to explore the efficacy and safety of nanoliposomal irinotecan and oxaliplatin combined with capecitabine as a novel conversion therapy for locally advanced colorectal cancer patients.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Colorectal Cancer
Disease stage
Required: Stage CT4N1-2M0, CT4BN0M0
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: surgery
Patients had not received systematic therapy, such as surgery, chemotherapy, radiotherapy, targeted therapy, or immunotherapy.
Cannot have received: chemotherapy
Patients had not received systematic therapy, such as surgery, chemotherapy, radiotherapy, targeted therapy, or immunotherapy.
Cannot have received: radiotherapy
Patients had not received systematic therapy, such as surgery, chemotherapy, radiotherapy, targeted therapy, or immunotherapy.
Cannot have received: targeted therapy
Patients had not received systematic therapy, such as surgery, chemotherapy, radiotherapy, targeted therapy, or immunotherapy.
Cannot have received: immunotherapy
Patients had not received systematic therapy, such as surgery, chemotherapy, radiotherapy, targeted therapy, or immunotherapy.
Lab requirements
Blood counts
Hemoglobin ≥90g/L; WBC ≥3.5×10^9/L; ANC ≥1.5×10^9/L; Platelet count ≥100×10^9/L
Kidney function
Serum creatinine ≤ ULN or creatinine clearance ≥60 ml/min
Liver function
Total serum bilirubin ≤1.5 ULN; AST/SGOT and ALT/SGPT ≤2.5 ULN
Adequate organ function according to the following laboratory test values: Hemoglobin value ≥90g/L. White blood cell count ≥3.5*10^9/L. Absolute neutrophil count ≥1.5*10^9/L. Platelet count ≥100*10^9/L. Serum creatinine ≤ ULN or creatinine clearance ≥60ml/min. Total serum bilirubin ≤1.5 ULN. AST/SGOT and ALT/SGPT ≤2.5 ULN.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06405139 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage CT4N1-2M0 or CT4BN0M0 is required.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages